1-3 of 3
Jonathan Strauss
Close
Sort by
Journal Articles

First in Human Study of an on/Off Switchable CAR-T Cell Platform Targeting CD19 for B Cell Malignancies (CLBR001 + SWI019)

Liana Nikolaenko, Carolyn Mulroney, Peter A. Riedell, Ian W. Flinn, Jose Carlos Cruz, Rakhee Vaidya, Koen van Besien, Michael Emde, Vadim Klyushnichenko, Jonathan Strauss, Eduardo Laborda, Jing Li, Mohit Trikha, Peter G. Schultz, Travis S Young
Journal: Blood
Blood (2021) 138 (Supplement 1): 2822.
https://doi.org/10.1182/blood-2021-151727
Published: 2021
Journal Articles

Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment

Baisong Mei, Clark Pan, Haiyan Jiang, Hendri Tjandra, Jonathan Strauss, Yaoqi Chen, Tongyao Liu, Xin Zhang, Joanne Severs, Jim Newgren, Jianmin Chen, Jian-Ming Gu, Babu Subramanyam, Michael A. Fournel, Glenn F. Pierce, John E. Murphy
Journal: Blood
Blood (2010) 116 (2): 270–279.
https://doi.org/10.1182/blood-2009-11-254755
Published: 2010
Journal Articles

Towards a New Therapy for Hemophilia A: Evaluation of Multiple Approaches To Prolong the In Vivo Efficacy of Recombinant Factor VIII.

John E. Murphy, Clark Pan, Baisong Mei, Jonathan Strauss, Hendri Tjandra, Liang Tang, Pamela Esmon, James Newgren, Gary Jesmok, Kyle Landskroner, Mohan Parmathi, Klaus-Peter Radtke, Joanne Severs, John Teare, Haiyan Jiang, Michael Fournel
Journal: Blood
Blood (2006) 108 (11): 1606.
https://doi.org/10.1182/blood.V108.11.1606.1606
Published: 2006